MASI
HealthcareMasimo Corporation · Medical - Devices · $9B
What is Masimo Corporation?
Masimo Corporation is a mid-cap healthcare company specializing in noninvasive patient monitoring technologies and hospital automation solutions used in clinical settings worldwide.
Masimo develops and markets advanced monitoring platforms that measure vital signs and blood parameters without invasive procedures. Revenue comes from selling monitoring devices, sensors, and software to hospitals and healthcare facilities. Its hospital automation platform connects patient data across care teams, aiming to improve safety and workflow efficiency.
Masimo was founded in 2007 and is headquartered in Irvine, California.
- SET pulse oximetry monitoring
- Rainbow SET Pulse CO-Oximetry platform
- SedLine brain function monitoring
- Masimo Hospital Automation platform
Is MASI a Good Stock to Buy?
UQS Score rates MASI as Below Average overall.
Among the five pillars, Risk stands out as the strongest area, suggesting the business carries a relatively manageable risk profile compared to many healthcare peers. Quality, Moat, Growth, and Valuation all register as Neutral, indicating no standout advantages or glaring weaknesses in those dimensions.
The absence of a clearly differentiated moat or strong growth signal means MASI does not rank highly against higher-scoring healthcare names.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MASI pay dividends?
No — Masimo Corporation does not currently pay a dividend.
Masimo does not currently pay a dividend. The company reinvests available capital into research, product development, and expanding its monitoring technology portfolio — a common approach for healthcare technology firms focused on long-term platform growth.
When does MASI report earnings?
Masimo reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Quarterly results reflect the company's ongoing transition toward a broader hospital automation and consumer health strategy alongside its core monitoring business. Performance trends are best evaluated in the context of the full UQS pillar profile rather than any single quarter.
For the most recent quarter's results, visit Masimo's investor relations page directly.
MASI Price History
-17.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Masimo Corporation?
Based on Masimo Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Masimo do?
Masimo develops noninvasive patient monitoring technologies, including pulse oximetry, brain function monitoring, and hemodynamic solutions. It also offers a hospital automation platform that connects patient data across clinical teams to support safer, more efficient care delivery.
Does MASI pay dividends?
No, Masimo does not pay a dividend. The company directs capital toward product development and expanding its monitoring and hospital automation platforms rather than returning cash to shareholders through distributions.
When does MASI report earnings?
Masimo reports on a quarterly basis. For confirmed dates and the most recent results, check the investor relations section of Masimo's official website.
Is MASI a good stock to buy?
UQS Score rates MASI as Below Average. Risk is the strongest pillar, while Quality, Moat, Growth, and Valuation are all Neutral. Investors seeking stronger composite scores may find higher-rated alternatives in the healthcare sector. View the full analysis on UQS Score.
Is MASI overvalued?
The UQS Valuation pillar for MASI is rated Neutral, suggesting the stock is neither clearly cheap nor obviously expensive relative to its fundamentals. The complete valuation breakdown is available to Pro members on UQS Score.
What is MASI's market cap bracket?
Masimo is classified as a mid-cap company, placing it between smaller niche medical device makers and the largest diversified healthcare conglomerates.
Is MASI a long-term quality indicator?
Based on the UQS composite, MASI scores Below Average overall. Long-term quality depends on sustained improvement across moat, growth, and quality pillars — areas currently rated Neutral. Pro members can track pillar trends over time on UQS Score.
What sector does MASI belong to?
Masimo operates in the Healthcare sector, specifically within medical devices and patient monitoring technology. It competes for hospital procurement budgets alongside other device and monitoring solution providers.
Unlock Full MASI Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare MASI against sector peers on a standardized scoring framework
- ✓Track score changes over time as new data becomes available
Pro Analysis
MASI — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 49.3 | 54.7 | 42.0 | 42.3 | 69.5 | 41.5 | 0.0 |
| May 16, 2026 | 49.3 | 54.7 | 42.0 | 42.3 | 69.5 | 41.6 | +7.5 |
| May 10, 2026 | 41.8 | 22.8 | 42.0 | 42.3 | 50.8 | 63.6 | 0.0 |
| May 8, 2026 | 41.8 | 22.8 | 42.0 | 42.3 | 50.8 | 63.5 | -3.9 |
| Apr 18, 2026 | 45.7 | 44.1 | 42.0 | 42.3 | 63.2 | 41.6 | -1.6 |
| Apr 12, 2026 | 47.3 | 44.1 | 42.0 | 42.3 | 63.2 | 52.0 | +0.2 |
| Apr 11, 2026 | 47.1 | 44.1 | 42.0 | 42.3 | 63.2 | 51.2 | 0.0 |
| Apr 2, 2026 | 47.1 | 43.9 | 42.0 | 42.2 | 63.2 | 51.3 | — |
MASI — Pillar Breakdown
Quality
— 54.7/100 (25%)Masimo Corporation has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 42.3/100 (20%)Masimo Corporation shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 69.5/100 (15%)Masimo Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 41.5/100 (15%)Masimo Corporation has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 42/100 (25%)Masimo Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MASI.
Score Composition
Financial Data
More Stock Analysis
How is the MASI UQS Score Calculated?
The UQS (Unified Quality Score) for Masimo Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Masimo Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Masimo Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.